Human prion disease: molecular pathogenesis, and possible therapeutic targets and strategies

References

• Watson N, Brandel J-P, Green A, et al. The importance of ongoing international surveillance for Creutzfeldt-Jakob disease. Nat Rev Neurol. 2021;17:362–379.
   PubMed Web of Science ®Google Scholar
• Baiardi S, Rossi M, Capellari S, et al. Recent advances in the histo-molecular pathology of human prion disease. Brain Pathol. 2019;29:278–300.
   PubMed Web of Science ®Google Scholar
• Parchi P, Giese A, Capellari S, et al. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol. 1999;46:224–233.
   PubMed Web of Science ®Google Scholar
• Parchi P, Strammiello R, Notari S, et al. Incidence and spectrum of sporadic Creutzfeldt-Jakob disease variants with mixed phenotype and co-occurrence of PrPSc types: an updated classification. Acta Neuropathol. 2009;118:659–671.
   PubMed Web of Science ®Google Scholar
• Baiardi S, Rossi M, Mammana A, et al. Phenotypic diversity of genetic Creutzfeldt-Jakob disease: a histo-molecular-based classification. Acta Neuropathol. 2021;142:707–728.
   PubMed Web of Science ®Google Scholar
• Prusiner SB. Prions. Proc Natl Acad Sci U S A. 1998;95:13363–13383.
   PubMed Web of Science ®Google Scholar
• Scheckel C, Aguzzi A. Prions, prionoids and protein misfolding disorders. Nat Rev Genet. 2018;19:405–418. doi: 10.1038/s41576-018-0011-4.
   PubMed Web of Science ®Google Scholar
• Büeler H, Aguzzi A, Sailer A, et al. Mice devoid of PrP are resistant to scrapie. Cell. 1993;73:1339–1347.
   PubMed Web of Science ®Google Scholar
• Watts JC, Bourkas MEC, Arshad H. The function of the cellular prion protein in health and disease. Acta Neuropathol. 2018;135:159–178.
   PubMed Web of Science ®Google Scholar
• Sweeney P, Park H, Baumann M, et al. Protein misfolding in neurodegenerative diseases: implications and strategies. Transl Neurodegener. 2017;6:6.
   PubMed Web of Science ®Google Scholar
• Yedidia Y, Horonchik L, Tzaban S, et al. Proteasomes and ubiquitin are involved in the turnover of the wild-type prion protein. Embo J. 2001;20:5383–5391.
   PubMed Web of Science ®Google Scholar
• Ma J, Lindquist S. Wild-type PrP and a mutant associated with prion disease are subject to retrograde transport and proteasome degradation. Proc Natl Acad Sci U S A. 2001;98:14955–14960.
   PubMed Web of Science ®Google Scholar
• Cox B, Ness F, Tuite M. Analysis of the generation and segregation of propagons: entities that propagate the [PSI+] prion in yeast. Genetics. 2003;165:23–33.
   PubMed Web of Science ®Google Scholar
• Kraus A, Hoyt F, Schwartz CL, et al. High-resolution structure and strain comparison of infectious mammalian prions. Mol Cell. 2021;81:4540–4551.e6.
   PubMed Web of Science ®Google Scholar
• Rouvinski A, Karniely S, Kounin M, et al. Live imaging of prions reveals nascent PrPSc in cell-surface, raft-associated amyloid strings and webs. J Cell Biol. 2014;204:423–441.
   PubMed Web of Science ®Google Scholar
• Ntt L, Wu B, Harris DA. Prion neurotoxicity. Brain Pathol. 2019;29:263–277.
   PubMed Web of Science ®Google Scholar
• Thellung S, Corsaro A, Dellacasagrande I, et al. Proteostasis unbalance in prion diseases: mechanisms of neurodegeneration and therapeutic targets. Front Neurosci. 2022;16:966019.
   PubMed Web of Science ®Google Scholar
• O’donovan CN, Tobin D, Cotter TG. Prion protein fragment PrP-(106-126) induces apoptosis via mitochondrial disruption in human neuronal SH-SY5Y cells. J Biol Chem. 2001;276:43516–43523.
   PubMed Web of Science ®Google Scholar
• Lakkaraju AKK, Frontzek K, Lemes E, et al. Loss of PIKfyve drives the spongiform degeneration in prion diseases. EMBO Mol Med. 2021;13:e14714.
   PubMed Web of Science ®Google Scholar
• Collinge J, Clarke AR. A general model of prion strains and their pathogenicity. Science. 2007;318(5852):930–936.
   PubMed Web of Science ®Google Scholar
• Aguzzi A, Akk L. Cell biology of prions and prionoids: a status report. Trends Cell Biol. 2016;26:40–51.
   PubMed Web of Science ®Google Scholar
• Fevrier B, Vilette D, Archer F, et al. Cells release prions in association with exosomes. Proc Natl Acad Sci U S A. 2004;101:9683–9688.
   PubMed Web of Science ®Google Scholar
• Gousset K, Schiff E, Langevin C, et al. Prions hijack tunnelling nanotubes for intercellular spread. Nat Cell Biol. 2009;11:328–336.
   PubMed Web of Science ®Google Scholar
• Parchi P, de Boni L, Saverioni D, et al. Consensus classification of human prion disease histotypes allows reliable identification of molecular subtypes: an inter-rater study among surveillance centres in Europe and USA. Acta Neuropathol. 2012;124:517–529.
   PubMed Web of Science ®Google Scholar
• Poggiolini I, Saverioni D, Parchi P. Prion protein misfolding, strains, and neurotoxicity: an update from studies on Mammalian prions. Int J Cell Biol. 2013;2013:910314.
   PubMedGoogle Scholar
• de Melo ASLF, Lima JLD, Malta MCS, et al. The role of microglia in prion diseases and possible therapeutic targets: a literature review. Prion. 2021;15:191–206.
   PubMed Web of Science ®Google Scholar
• Sanders WL. Creutzfeldt-Jakob disease treated with amantadine. J Neurol Neurosurg Psychiatry. 1979;42:960–961.
   PubMed Web of Science ®Google Scholar
• Braham J. Jakob-Creutzfeldt disease: treatment by amantadine. Br Med J. 1971;4:212–213.
   PubMedGoogle Scholar
• Sanders WL, Dunn TL. Creutzfeldt-Jakob disease treated with amantidine. A report of two cases. J Neurol Neurosurg Psychiatry. 1973;36:581–584.
   PubMed Web of Science ®Google Scholar
• Scully R, Galdabini J, McNeely B. Case records of the massachusetts general hospital. N Engl J Med. 1980;303:1162–1171.
   PubMedGoogle Scholar
• Ratcliffe J, Rittman A, Wolf S, et al. Creutzfeldt-Jakob disease with focal onset unsuccessfully treated with amantadine. Bull Los Angeles Neurol Soc. 1975;40:18–20.
   PubMedGoogle Scholar
• Terzano MG, Montanari E, Calzetti S, et al. The effect of amantadine on arousal and EEG patterns in Creutzfeldt-Jakob disease. Arch Neurol. 1983;40:555–559.
   PubMedGoogle Scholar
• Neri G, Figà-Talamanca L, Di Battista GC, et al. Amantadine in Creutzfeldt-Jakob disease. Review of the literature and case contribution. Riv Neurobiol. 1984;30:47–56.
   PubMedGoogle Scholar
• Stewart LA, Rydzewska LHM, Keogh GF, et al. Systematic review of therapeutic interventions in human prion disease. Neurology. 2008;70:1272–1281.
   PubMed Web of Science ®Google Scholar
• David AS, Grant R, Ballantyne JP. Unsuccessful treatment of Creutzfeldt-Jakob disease with acyclovir. Lancet. 1984;1:512–513.
   PubMed Web of Science ®Google Scholar
• Newman PK. Acyclovir in Creutzfeldt-Jakob disease. Lancet. 1984;1:793.
   PubMed Web of Science ®Google Scholar
• Kovanen J, Haltia M, Cantell K. Failure of interferon to modify Creutzfeldt-Jakob disease. Br Med J. 1980;280:902.
   PubMedGoogle Scholar
• Dhar S, Bitting RL, Rylova SN, et al. Flupirtine blocks apoptosis in batten patient lymphoblasts and in human postmitotic CLN3- and CLN2-deficient neurons. Ann Neurol. 2002;51:448–466.
   PubMed Web of Science ®Google Scholar
• Perovic S, Schröder HC, Pergande G, et al. Effect of flupirtine on Bcl-2 and glutathione level in neuronal cells treated in vitro with the prion protein fragment (PrP106-126). Exp Neurol. 1997;147:518–524.
   PubMed Web of Science ®Google Scholar
• Otto M, Cepek L, Ratzka P, et al. Efficacy of flupirtine on cognitive function in patients with CJD: a double-blind study. Neurology. 2004;62:714–718.
   PubMed Web of Science ®Google Scholar
• Caughey B, Raymond GJ. Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells. J Virol. 1993;67:643–650.
   PubMed Web of Science ®Google Scholar
• Doh-Ura K, Ishikawa K, Murakami-Kubo I, et al. Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. J Virol. 2004;78:4999–5006.
   PubMed Web of Science ®Google Scholar
• Bone I, Belton L, Walker AS, et al. Intraventricular pentosan polysulphate in human prion diseases: an observational study in the UK. Eur J Neurol. 2008;15:458–464.
   PubMed Web of Science ®Google Scholar
• Tsuboi Y, Doh-Ura K, Yamada T. Continuous intraventricular infusion of pentosan polysulfate: clinical trial against prion diseases. Neuropathology. 2009;29:632–636.
   PubMed Web of Science ®Google Scholar
• Honda H, Sasaki K, Minaki H, et al. Protease-resistant PrP and PrP oligomers in the brain in human prion diseases after intraventricular pentosan polysulfate infusion. Neuropathology. 2012;32:124–132.
   PubMed Web of Science ®Google Scholar
• Kamatari YO, Hayano Y, Yamaguchi K, et al. Characterizing antiprion compounds based on their binding properties to prion proteins: implications as medical chaperones. Protein Sci. 2013;22:22–34.
   PubMed Web of Science ®Google Scholar
• Doh-Ura K, Iwaki T, Caughey B. Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J Virol. 2000;74:4894–4897.
   PubMed Web of Science ®Google Scholar
• Korth C, May BC, Cohen FE, et al. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci U S A. 2001;98:9836–9841.
   PubMed Web of Science ®Google Scholar
• Collins SJ, Lewis V, Brazier M, et al. Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Ann Neurol. 2002;52:503–506.
   PubMed Web of Science ®Google Scholar
• Barret A, Tagliavini F, Forloni G, et al. Evaluation of quinacrine treatment for prion diseases. J Virol. 2003;77:8462–8469.
   PubMed Web of Science ®Google Scholar
• Murakami-Kubo I, Doh-Ura K, Ishikawa K, et al. Quinoline derivatives are therapeutic candidates for transmissible spongiform encephalopathies. J Virol. 2004;78:1281–1288.
   PubMed Web of Science ®Google Scholar
• Nakajima M, Yamada T, Kusuhara T, et al. Results of quinacrine administration to patients with Creutzfeldt-Jakob disease. Dement Geriatr Cognit Disord. 2004;17:158–163.
   PubMed Web of Science ®Google Scholar
• Haïk S, Brandel JP, Salomon D, et al. Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects. Neurology. 2004;63:2413–2415.
   PubMed Web of Science ®Google Scholar
• Collinge J, Gorham M, Hudson F, et al. Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurol. 2009;8:334–344.
   PubMed Web of Science ®Google Scholar
• Geschwind MD, Kuo AL, Wong KS, et al. Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease. Neurology. 2013;81:2015–2023.
   PubMed Web of Science ®Google Scholar
• Ghaemmaghami S, Ahn M, Lessard P, et al. Continuous quinacrine treatment results in the formation of drug-resistant prions. PLOS Pathog. 2009;5:e1000673.
   PubMed Web of Science ®Google Scholar
• Tagliavini F, Forloni G, Colombo L, et al. Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro. J Mol Biol. 2000;300:1309–1322.
   PubMed Web of Science ®Google Scholar
• Forloni G, Iussich S, Awan T, et al. Tetracyclines affect prion infectivity. Proc Natl Acad Sci U S A. 2002;99:10849–10854.
   PubMed Web of Science ®Google Scholar
• De Luigi A, Colombo L, Diomede L, et al. The efficacy of tetracyclines in peripheral and intracerebral prion infection. PLoS ONE. 2008;3:e1888.
   PubMed Web of Science ®Google Scholar
• Haïk S, Marcon G, Mallet A, et al. Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13:150–158.
   PubMed Web of Science ®Google Scholar
• Varges D, Manthey H, Heinemann U, et al. Doxycycline in early CJD: a double-blinded randomised phase II and observational study. J Neurol Neurosurg Psychiatry. 2017;88:119–125.
   PubMed Web of Science ®Google Scholar
• Forloni G, Tettamanti M, Lucca U, et al. Preventive study in subjects at risk of fatal familial insomnia: innovative approach to rare diseases. Prion. 2015;9:75–79.
   PubMed Web of Science ®Google Scholar
• Forloni G, Roiter I, Artuso V, et al. Preventive pharmacological treatment in subjects at risk for fatal familial insomnia: science and public engagement. Prion. 2022;16:66–77.
   PubMed Web of Science ®Google Scholar
• van Dyck CH. Anti-amyloid-β monoclonal antibodies for alzheimer’s disease: pitfalls and promise. Biol Psychiatry. 2018;83:311–319.
   PubMed Web of Science ®Google Scholar
• Antonini A, Bravi D, Sandre M, et al. Immunization therapies for Parkinson’s disease: state of the art and considerations for future clinical trials. Expert Opin Investig Drugs. 2020;29:685–695.
   PubMed Web of Science ®Google Scholar
• Aguzzi A, Lakkaraju AKK, Frontzek K. Toward therapy of human prion diseases. Annu Rev Pharmacol Toxicol. 2018;58:331–351.
   PubMed Web of Science ®Google Scholar
• Ma Y, Ma J. Immunotherapy against Prion Disease. Pathogens. 2020;9:216.
   PubMed Web of Science ®Google Scholar
• Schwarz A, Krätke O, Burwinkel M, et al. Immunisation with a synthetic prion protein-derived peptide prolongs survival times of mice orally exposed to the scrapie agent. Neurosci Lett. 2003;350:187–189.
   PubMed Web of Science ®Google Scholar
• Petsch B, Müller-Schiffmann A, Lehle A, et al. Biological effects and use of PrPSc- and PrP-specific antibodies generated by immunization with purified full-length native mouse prions. J Virol. 2011;85:4538–4546.
   PubMed Web of Science ®Google Scholar
• Nitschke C, Flechsig E, van den Brandt J, et al. Immunisation strategies against prion diseases: prime-boost immunisation with a PrP DNA vaccine containing foreign helper T-cell epitopes does not prevent mouse scrapie. Vet Microbiol. 2007;123:367–376.
   PubMed Web of Science ®Google Scholar
• Weissmann C. A “unified theory” of prion propagation. Nature. 1991;352:679–683.
   PubMed Web of Science ®Google Scholar
• Mallucci G, Dickinson A, Linehan J, et al. Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science. 2003;302:871–874.
   PubMed Web of Science ®Google Scholar
• Bendheim PE, Barry RA, DeArmond SJ, et al. Antibodies to a scrapie prion protein. Nature. 1984;310:418–421.
   PubMed Web of Science ®Google Scholar
• Gabizon R, McKinley MP, Groth D, et al. Immunoaffinity purification and neutralization of scrapie prions. Prog clin biol res. 1989;317:583–600.
   PubMedGoogle Scholar
• Heppner FL, Musahl C, Arrighi I, et al. Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science. 2001;294:178–182.
   PubMed Web of Science ®Google Scholar
• Frontzek K, Aguzzi A. Recent developments in antibody therapeutics against prion disease. Emerg Top Life Sci. 2020;4:169–173.
   PubMedGoogle Scholar
• Peretz D, Williamson RA, Kaneko K, et al. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature. 2001;412:739–743.
   PubMed Web of Science ®Google Scholar
• Sonati T, Reimann RR, Falsig J, et al. The toxicity of antiprion antibodies is mediated by the flexible tail of the prion protein. Nature. 2013;501:102–106.
   PubMed Web of Science ®Google Scholar
• Reimann RR, Sonati T, Hornemann S, et al. Differential toxicity of antibodies to the prion protein. PLOS Pathog. 2016;12:e1005401.
   PubMed Web of Science ®Google Scholar
• Wu B, McDonald AJ, Markham K, et al. The N-terminus of the prion protein is a toxic effector regulated by the C-terminus. Elife. 2017;6:e23473.
   PubMed Web of Science ®Google Scholar
• Frontzek K, Bardelli M, Senatore A, et al. A conformational switch controlling the toxicity of the prion protein. Nat Struct Mol Biol. 2022;29:831–840.
   PubMed Web of Science ®Google Scholar
• Lefebvre-Roque M, Kremmer E, Gilch S, et al. Toxic effects of intracerebral PrP antibody administration during the course of BSE infection in mice. Prion. 2007;1:198–206.
   PubMed Web of Science ®Google Scholar
• White AR, Enever P, Tayebi M, et al. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature. 2003;422:80–83.
   PubMed Web of Science ®Google Scholar
• Klöhn P-C, Farmer M, Linehan JM, et al. PrP antibodies do not trigger mouse hippocampal neuron apoptosis. Science. 2012;335:52.
   PubMed Web of Science ®Google Scholar
• Mead S, Khalili-Shirazi A, Potter C, et al. Prion protein monoclonal antibody (PRN100) therapy for Creutzfeldt-Jakob disease: evaluation of a first-in-human treatment programme. Lancet Neurol. 2022;21:342–354.
   PubMed Web of Science ®Google Scholar
• Büeler H, Raeber A, Sailer A, et al. High prion and PrPSc levels but delayed onset of disease in scrapie-inoculated mice heterozygous for a disrupted PrP gene. Mol Med. 1994;1:19–30.
   PubMed Web of Science ®Google Scholar
• Safar JG, DeArmond SJ, Kociuba K, et al. Prion clearance in bigenic mice. J Gen Virol. 2005;86:2913–2923.
   PubMed Web of Science ®Google Scholar
• Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377:1723–1732.
   PubMed Web of Science ®Google Scholar
• Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, et al. Targeting huntingtin expression in patients with huntington’s disease. N Engl J Med. 2019;380:2307–2316.
   PubMed Web of Science ®Google Scholar
• Büeler H, Fischer M, Lang Y, et al. Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature. 1992;356:577–582.
   PubMed Web of Science ®Google Scholar
• Richt JA, Kasinathan P, Hamir AN, et al. Production of cattle lacking prion protein. Nat Biotechnol. 2007;25:132–138.
   PubMed Web of Science ®Google Scholar
• Benestad SL, Austbø L, Tranulis MA, et al. Healthy goats naturally devoid of prion protein. Vet Res. 2012;43:87.
   PubMed Web of Science ®Google Scholar
• Bremer J, Baumann F, Tiberi C, et al. Axonal prion protein is required for peripheral myelin maintenance. Nat Neurosci. 2010;13:310–318.
   PubMed Web of Science ®Google Scholar
• Küffer A, Lakkaraju AKK, Mogha A, et al. The prion protein is an agonistic ligand of the G protein-coupled receptor Adgrg6. Nature. 2016;536:464–468.
   PubMed Web of Science ®Google Scholar
• Minikel EV, Vallabh SM, Lek M, et al. Quantifying prion disease penetrance using large population control cohorts. Sci Transl Med. 2016;8:322ra9.
   PubMed Web of Science ®Google Scholar
• Minikel EV, Karczewski KJ, Martin HC, et al. Evaluating drug targets through human loss-of-function genetic variation. Nature. 2020;581:459–464.
   PubMed Web of Science ®Google Scholar
• Minikel EV, Zhao HT, Le J, et al. Prion protein lowering is a disease-modifying therapy across prion disease stages, strains and endpoints. Nucleic Acids Res. 2020;48:10615–10631.
   PubMed Web of Science ®Google Scholar
• White MD, Farmer M, Mirabile I, et al. Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease. Proc Natl Acad Sci U S A. 2008;105:10238–10243.
   PubMed Web of Science ®Google Scholar
• Silber BM, Gever JR, Rao S, et al. Novel compounds lowering the cellular isoform of the human prion protein in cultured human cells. Bioorg Med Chem. 2014;22:1960–1972.
   PubMed Web of Science ®Google Scholar
• Ahn M, Bajsarowicz K, Oehler A, et al. Convection-enhanced delivery of AAV2-PrPshRNA in prion-infected mice. PLoS ONE. 2014;9:e98496.
   PubMed Web of Science ®Google Scholar
• Nazor Friberg K, Hung G, Wancewicz E, et al. Intracerebral infusion of antisense oligonucleotides into prion-infected mice. Mol Ther Nucleic Acids. 2012;1:e9.
   PubMedGoogle Scholar
• Raymond GJ, Zhao HT, Race B, et al. Antisense oligonucleotides extend survival of prion-infected mice. JCI Insight. 2019;5:e131175.
   PubMed Web of Science ®Google Scholar
• Reidenbach AG, Minikel EV, Zhao HT, et al. Characterization of the prion protein binding properties of antisense oligonucleotides. Biomolecules. 2019;10:1.
   PubMed Web of Science ®Google Scholar
• Klug GMJA, Wand H, Simpson M, et al. Intensity of human prion disease surveillance predicts observed disease incidence. J Neurol Neurosurg Psychiatry. 2013;84:1372–1377.
   PubMed Web of Science ®Google Scholar
• Goldman JS, Vallabh SM. Genetic counseling for prion disease: updates and best practices. Genet Med. 2022;24:1993–2003.
   PubMed Web of Science ®Google Scholar
• Minikel EV, Vallabh SM, Orseth MC, et al. Age at onset in genetic prion disease and the design of preventive clinical trials. Neurology. 2019;93:e125–134.
   PubMed Web of Science ®Google Scholar
• Heinemann U, Krasnianski A, Meissner B, et al. Creutzfeldt-Jakob disease in Germany: a prospective 12-year surveillance. Brain. 2007;130:1350–1359.
   PubMed Web of Science ®Google Scholar
• Bishop MT, Will RG, Manson JC. Defining sporadic Creutzfeldt-Jakob disease strains and their transmission properties. Proc Natl Acad Sci U S A. 2010;107:12005–12010.
   PubMed Web of Science ®Google Scholar
• Rossi M, Baiardi S, Parchi P. Understanding prion strains: evidence from studies of the disease forms affecting humans. Viruses. 2019;11:309.
   PubMed Web of Science ®Google Scholar
• Candelise N, Baiardi S, Franceschini A, et al. Towards an improved early diagnosis of neurodegenerative diseases: the emerging role of in vitro conversion assays for protein amyloids. Acta Neuropathol Commun. 2020;8:117.
   PubMed Web of Science ®Google Scholar
• Rübsamen N, Pape S, Konigorski S, et al. Diagnostic accuracy of cerebrospinal fluid biomarkers for the differential diagnosis of sporadic Creutzfeldt-Jakob disease: a (network) meta-analysis. Eur J Neurol. 2022;29:1366–1376.
   PubMed Web of Science ®Google Scholar
• Poleggi A, Baiardi S, Ladogana A, et al. The use of real-time quaking-induced conversion for the diagnosis of human prion diseases. Front Aging Neurosci. 2022;14:874734.
   PubMed Web of Science ®Google Scholar
• Hermann P, Laux M, Glatzel M, et al. Validation and utilization of amended diagnostic criteria in Creutzfeldt-Jakob disease surveillance. Neurology. 2018;91:e331–338.
   PubMed Web of Science ®Google Scholar
• Rhoads DD, Wrona A, Foutz A, et al. Diagnosis of prion diseases by RT-Quic results in improved surveillance. Neurology. 2020;95:e1017–1026.
   PubMed Web of Science ®Google Scholar
• Watson N, Hermann P, Ladogana A, et al. Validation of revised international creutzfeldt-jakob disease surveillance network diagnostic criteria for sporadic creutzfeldt-jakob disease. JAMA Netw Open. 2022;5:e2146319.
   PubMed Web of Science ®Google Scholar
• Mastrangelo A, Mammana A, Baiardi S, et al. Evaluation of the impact of CSF prion RT-Quic and amended criteria on the clinical diagnosis of Creutzfeldt-Jakob disease: a 10-year study in Italy. J Neurol Neurosurg Psychiatry. 2022;94(2):121–129. DOI:10.1136/jnnp-2022-330153
   PubMed Web of Science ®Google Scholar
• Vallabh SM, Minikel EV, Williams VJ, et al. Cerebrospinal fluid and plasma biomarkers in individuals at risk for genetic prion disease. BMC Med. 2020;18:140.
   PubMed Web of Science ®Google Scholar
• Mok TH, Nihat A, Majbour N, et al. Trajectories of neurodegeneration and seed amplification biomarkers prior to disease onset in individuals at risk of prion disease. Brain. 2022:awad101. DOI:10.1093/brain/awad101
   PubMed Web of Science ®Google Scholar
• Sano K, Satoh K, Atarashi R, et al. Early detection of abnormal prion protein in genetic human prion diseases now possible using real-time QUIC assay. PLoS ONE. 2013;8:e54915.
   PubMed Web of Science ®Google Scholar
• Lattanzio F, Abu-Rumeileh S, Franceschini A, et al. Prion-specific and surrogate CSF biomarkers in Creutzfeldt-Jakob disease: diagnostic accuracy in relation to molecular subtypes and analysis of neuropathological correlates of p-tau and Aβ42 levels. Acta Neuropathol. 2017;133:559–578.
   PubMed Web of Science ®Google Scholar
• Franceschini A, Baiardi S, Hughson AG, et al. High diagnostic value of second generation CSF RT-Quic across the wide spectrum of CJD prions. Sci Rep. 2017;7:10655.
   PubMed Web of Science ®Google Scholar
• Bongianni M, Orrù C, Groveman BR, et al. Diagnosis of human prion disease using real-time quaking-induced conversion testing of olfactory mucosa and cerebrospinal fluid samples. JAMA Neurol. 2017;74:155–162.
   PubMed Web of Science ®Google Scholar
• Foutz A, Appleby BS, Hamlin C, et al. Diagnostic and prognostic value of human prion detection in cerebrospinal fluid. Ann Neurol. 2017;81:79–92.
   PubMed Web of Science ®Google Scholar
• Mok TH, Nihat A, Luk C, et al. Bank vole prion protein extends the use of RT-Quic assays to detect prions in a range of inherited prion diseases. Sci Rep. 2021;11:5231.
   PubMed Web of Science ®Google Scholar
• Cramm M, Schmitz M, Karch A, et al. Stability and reproducibility underscore utility of RT-Quic for diagnosis of creutzfeldt-jakob disease. Mol Neurobiol. 2016;53:1896–1904.
   PubMed Web of Science ®Google Scholar
• Cortelli P, Perani D, Montagna P, et al. Presymptomatic diagnosis in fatal familial insomnia: serial neurophysiological and 18FDG-PET studies. Brain. 2006;129:668–675.
   PubMed Web of Science ®Google Scholar
• Cohen OS, Chapman J, Korczyn AD, et al. Familial Creutzfeldt-Jakob disease with the E200K mutation: longitudinal neuroimaging from asymptomatic to symptomatic CJD. J Neurol. 2015;262:604–613.
   PubMed Web of Science ®Google Scholar
• Novi G, Canosa A, Nobili F, et al. Longitudinal brain magnetic resonance imaging and real-time quaking induced conversion analysis in presymptomatic Creutzfeldt-Jakob disease. Eur J Neurol. 2018;25:e127–128.
   PubMed Web of Science ®Google Scholar
• Mole J, Mead S, Rudge P, et al. Cognitive decline heralds onset of symptomatic inherited prion disease. Brain. 2021;144:989–998.
   PubMed Web of Science ®Google Scholar
• McNiven K, Nihat A, Mok TH, et al. Enteral feeding is associated with longer survival in the advanced stages of prion disease. Brain Commun. 2019;1:fcz012.
   PubMedGoogle Scholar
• Miller TM, Cudkowicz ME, Genge A, et al. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2022;387:1099–1110.
   PubMed Web of Science ®Google Scholar
• Staffaroni AM, Kramer AO, Casey M, et al. Association of blood and cerebrospinal fluid tau level and other biomarkers with survival time in sporadic creutzfeldt-jakob disease. JAMA Neurol. 2019;76:969–977.
   PubMed Web of Science ®Google Scholar
• Abu-Rumeileh S, Baiardi S, Ladogana A, et al. Comparison between plasma and cerebrospinal fluid biomarkers for the early diagnosis and association with survival in prion disease. J Neurol Neurosurg Psychiatry. 2020;91:1181–1188.
   PubMed Web of Science ®Google Scholar
• Hyare H, De Vita E, Porter M-C, et al. Putaminal diffusion tensor imaging measures predict disease severity across human prion diseases. Brain Commun. 2020;2:fcaa032.
   PubMedGoogle Scholar
• Thompson AGB, Lowe J, Fox Z, et al. The Medical Research Council prion disease rating scale: a new outcome measure for prion disease therapeutic trials developed and validated using systematic observational studies. Brain. 2013;136:1116–1127.
   PubMed Web of Science ®Google Scholar
• Nihat A, Mok TH, Odd H, et al. Development of novel clinical examination scales for the measurement of disease severity in Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry. 2022;93:404–412.
   PubMed Web of Science ®Google Scholar
• Jones E, Hummerich H, Viré E, et al. Identification of novel risk loci and causal insights for sporadic Creutzfeldt-Jakob disease: a genome-wide association study. Lancet Neurol. 2020;19(10):840–848. DOI:10.1016/S1474-4422(20)30273-8
   PubMed Web of Science ®Google Scholar
• Jones E, Hill E, Linehan J, et al. Knockout of sporadic creutzfeldt-jakob disease risk gene Stx6 in mice extends prion disease incubation time BioRxiv; 2023. DOI: 10.1101/2023.01.10.523281.
   Google Scholar
• Nihat A, Ranson JM, Harris D, et al. Development of prognostic models for survival and care status in sporadic Creutzfeldt-Jakob disease. Brain Commun. 2022;4:fcac201.
   PubMedGoogle Scholar
• Llorens F, Rübsamen N, Hermann P, et al. A prognostic model for overall survival in sporadic Creutzfeldt-Jakob disease. Alzheimers Dement. 2020;16:1438–1447.
   PubMed Web of Science ®Google Scholar